Our patients can schedule a COVID-19 vaccination through NYU Langone Health MyChart or the NYU Langone Health app. Learn more about the COVID-19 vaccine. Read our updated information about wearing a mask for your visit.

If you need help accessing our website, call 855-698-9991
Skip to main content
Affiliated Provider
Affiliated providers provide medical care at an NYU Langone location or a private practice, and are not employed by NYU Langone Health.

Michael B. Whitlow, MD

Affiliated Provider
Affiliated providers provide medical care at an NYU Langone location or a private practice, and are not employed by NYU Langone Health.
  • Specialty: Dermatology
  • Language: English
  • Phone: 212-753-5382
View Locations

Conditions and Treatments

Board Certifications
  • American Board of Dermatology (Clinical & Lab Dermatological Immu), 1989
  • American Board of Dermatology - Dermatology, 1988
Education and Training
  • Residency, NYU Medical Center, 1988
  • MD from Johns Hopkins University, 1984

Is this your profile?

Edit profile

This provider accepts the following insurance plans.

  • Aetna
    • Aetna HMO
    • Aetna Indemnity
    • Aetna Medicare
    • Aetna POS
    • Aetna PPO/EPO
  • Cigna
    • Cigna EPO/POS
    • Cigna PPO
This list of insurances changes regularly, and insurance plans listed may not be accepted at all office locations for this provider. Before your appointment, please confirm with your insurance company that this provider accepts your insurance.

Locations and Appointments

Michael Whitlow, M.D.

635 Madison Avenue
New York, NY 10022

Interests

terminal complement proteins

Research Summary

Our goal is to better understand how the terminal complement proteins damage cell membranes and how cells protect themselves from such complement damage. Complement-induced membrane damage is mediated by the terminal complement proteins C5- C9. When activated, these terminal complement proteins form transmembrane channels in the membrane of nearby cells. We found that complement channels are not formed randomly but within membrane domains. If complement preferentially localizes to membrane domains, a receptor must be within the domains for one or more of the terminal complement proteins. Aterminal complement proteinss the initial interaction between the terminal complement proteins and the membrane occurs with C5b6, this complex is the most likely ligand of such a receptor.

We identified these molecules on the erythrocyte surface that the terminal complement proteins bind to: anionic phospholipids, gangliosides, and sialic acid present on glycophorin. We have also shown that the stage of complement channel formation at which this interaction occurs is at the stage of C5b6 binding to the membrane. The focus of our research now is to understand how C5b6 interacts with these anionic molecules and to use this information to develop soluble inhibitors of the terminal complement proteins. This work is clinically important because the terminal complement proteins are a primary focus in the destruction of xenogeneic grafts, i.e., grafts between species. Inhibitors such as the ones we are developing may increase the ability of these xenografts to be used in transplantation.

 

 

These focus areas and their associated publications are derived from PubMed and the MeSH term library. *
represents one publication
Loading...
*Due to PubMed processing times, the most recent publications may not be reflected in the timeline.

  • Tran, Kathleen; Boyd, Kevin P; Robinson, Maria R; Whitlow, Michael

    Dermatology online journal. 2013 Dec 16; 19(12):20718

  • Aquatic dermatology

    Whitlow M

    Current dermatologic diagnosis & treatment. Philadelphia : Lippincott Williams & Wilkins, 2001. p.16-17. (3678)

  • Pyoderma gangrenosum

    Kim L; Whitlow M

    Current dermatologic diagnosis & treatment. Philadelphia : Lippincott Williams & Wilkins, 2001. p.184-185. (3753)

Read All Publications (32)